Temporal arteritis: Treatment, follow up and prognosis;Maladie de Horton et pseudopolyarthrite rhizomélique : nouveautés thérapeutiques ? Évolution et pronostic

Revue de Medecine Interne

Volumn 29, Issue SUPPL. 3, 2008, Pages

  Duhaut, P ^a  

^a AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

Follow up; Temporal arteritis; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; ANTICOAGULANT AGENT; AZATHIOPRINE; CALCIUM; CLODRONIC ACID; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETIDRONIC ACID; HEPARIN; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; PREDNISONE; RISEDRONIC ACID; VITAMIN D;

ARTICLE; BONE DENSITY; CARDIOVASCULAR DISEASE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFECT; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; META ANALYSIS; MONOTHERAPY; PROGNOSIS; REMISSION; RHEUMATIC POLYMYALGIA; SYSTEMATIC REVIEW; TEMPORAL ARTERITIS;

AGING; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; DRUG THERAPY, COMBINATION; GIANT CELL ARTERITIS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; POLYMYALGIA RHEUMATICA; PROGNOSIS; RISK FACTORS; SEX DISTRIBUTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 56549119011     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2008.10.008     Document Type: Article

References (43)

1. Hunder G.G., Sheps S.G., Allen G.L., and Joyce J.W. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann Intern Med 82 (1975) 613-618
2. Chevalet P., Barrier J.H., Pottier P., Magadur-Joly G., Pottier M.A., Hamidou M., et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the treatment of simple forms of giant cell arteritis: a one year follow-up study of 164 patients. J Rheumatol 27 (2000) 1484-1491
3. Maslumzadeh M., Hunder G.G., Easley K.A., Calamia K.T., Matteson E.L., Griffing W.L., et al. Treatment of giant cell artertitis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 54 (2006) 3310-3318
4. Nordborg E., Schaufelberger C., Andersson R., Bosaeus I., and Bengtsson B.A. The ineffectiveness of cyclical oral clodronate on bone mineral density in glucocorticoid-treated patients with giant cell arteritis. J Intern Med 242 (1997) 367-371
5. Cortet B., Hachulla E., Barton I., Bonvoisin B., and Roux C. Evaluation of the efficacy of etidronate therapy in preventig glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study. Rev Rhum Engl Ed 66 (1999) 214-219
6. Healey J.H., Paget S.A., Williams-Russo P., Szatrowski T.P., Schneider R., Spiera H., et al. A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica. Calcif Tissue Int 58 (1996) 73-80
7. Lippuner K. Medical treatment of vertebral osteoporosis. Eur Spine J 12 (2003) S132-S141
8. Van der Veen M.J., Dinant H.J., Van Booma-Frankfort C., Van Albada-Kuipers G.A., and Bijlsma J.W. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?. Ann Rheum Dis 55 (1996) 218-223
9. Jover J.A., Hernandez-Garcia C., Morado I.C., Vargas E., Banares A., and Fernandez-Gutierrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone, a randomized, double-blind, placebo-controlled trial. Ann Intern Med 134 (2001) 106-114
10. Spiera R.F., Mitnick H.J., Kupersmith M., Richmond M., Spiera H., Peterson M.G., et al. A prospective, double-blind, randomized, placebo-controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 19 (2001) 495-501
11. Caporali R., Cimmino M.A., Ferraccioli G., Gerli R., Klersy C., Salvarani C., et al., Systemic Vasculitis Study Group of the Italian Society for Rheumatology. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 141 (2004) 493-500
12. Hoffman G.S., Cid M.C., Hellmann D.B., Guillevin L., Stone J.H., Schousboe J., et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 46 (2002) 1309-1318
13. Schaufelberger C., Andersson R., and Nordborg E. No additive effect of cyclosporin A compared with glucocorticoid treatment alone in giant cell arteritis: results of an open, controlled, randomized study. Br J Rheumatol 37 (1998) 464-465
14. Schaufelberger C., Mollby H., Uddhammar A., Bratt J., and Nordborg E. No additional steroid-sparing effect of cyclosporine A in giant cell arteritis. Scand J Rheumatol 35 (2006) 327-329
15. De Silva M., and Hazleman B.L. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 45 (1986) 136-138
16. Cantini F., Niccoli L., Salvarani C., Padula A., and Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 44 (2001) 2933-2935
17. Andonopoulos A.P., Meimaris N., Daoussis D., Bounas A., and Giannopoulos G. Experience with infliximab (anti-TNFá monoclonal antibody) as monotherapy for giant cell arteritis. Ann Rheum Dis 62 (2003) 1116
18. Tan A.L., Holdsworth J., Pease C., Emery P., and McGonagle D. Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis 62 (2003) 373-374
19. Hoffman G.S., Cid M.C., Rendt-Zagar K.E., Merkel P.A., Weyand C.M., Stone J.H., et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 146 (2007) 621-630
20. Salvarani C., Macchioni P., Manzini C., Paolazzi G., Trotta A., Manganelli P., et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med 146 (2007) 631-639
21. Weyand C.M., and Goronzy J.J. Medium- and large-vessel vasculitis. N Engl J Med 349 (2003) 160-169
22. Nesher G., Berkun Y., Mates M., Baras M., Rubinow A., and Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 50 (2004) 1332-1337
23. Lee M.S., Smith S.D., Galor A., and Hoffman G.S. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 54 (2006) 3306-3309
24. Barrier J., Tournemaine N., Maulaz D., Mainguy-Fonteneau B., Rojouan J., Potel G., et al. Évolution, traitement et pronostic de la maladie de Horton. Ann Med Interne (Paris) 134 (1983) 428-435
25. Nordborg E., and Bengtsson B.A. Death rates and causes of death in 284 consecutive patients with giant cell arteritis confirmed by biopsy. BMJ 299 (1989) 549-550
26. Andersson R., Malmvall B.E., and Bengtsson B.A. Long-term survival in giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Acta Med Scand 220 (1986) 361-364
27. Uddhammar A., Eriksson A.L., Nystrom L., Stenling R., and Rantapaa-Dahlqvist S. Increased mortality due to cardiovascular disease in patients with giant cell arteritis in Northern Sweden. J Rheumatol 29 (2002) 737-742
28. Gran J.T., and Myklebust G. The incidence of polymyalgia rheumatica and temporal arteritis in the county of Aust Agder, South Norway: a prospective study 1987-1994. J Rheumatol 24 (1997) 1739-1743
29. Matteson E.L., Gold K.N., Bloch D.A., and Hunder G.G. Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort. Am J Med 100 (1996) 193-196
30. Le Page L., Duhaut P., Seydoux D., Bosshard S., Ecochard R., Abbas F., et al. Incidence des accidents cardiovasculaires au cours de la maladie de Horton : résultats préliminaires de l'étude prospective en double cohorte GRACG. Rev Med Interne 27 (2006) 98-105
31. Duhaut P., Pinede L., Bornet H., Demolombe-Rague S., Dumontet C., Ninet J., et al., Groupe de recherche sur l'artérite à cellules géantes (GRACG). Biopsy proven and biopsy negative temporal arteritis: differences in clinical spectrum at the onset of the disease. Ann Rheum Dis 58 (1999) 335-341
32. Liozon F., Vidal E., Gaches F., Venot J., Liozon E., Cransac M., et al. Les décès dans la maladie de Horton. Facteurs de pronostic. Rev Med Interne 13 (1992) 187-191
33. Gonzalez-Gay M.A., Blanco R., Abraira V., Garcia-Porrua C., Ibanez D., Garcia-Pais M.J., et al. Giant cell arteritis in Lugo, Spain, is associated with low long-term mortality. J Rheumatol 24 (1997) 2171-2176
34. Gonzalez-Gay M.A., Garcia-Porrua C., Vazquez-Caruncho M., Dababneh A., Hajeer A., and Ollier W.E. The spectrum of polymyalgia rheumatica in North-western Spain: incidence and analysis of variables associated with relapse in a ten-year study. J Rheumatol 26 (1999) 1236-1332
35. Salvarani C., Cantini F., Niccoli L., Macchioni P., Consonni D., Bajocchi G., et al. Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective follow up study. Arthritis Rheum 53 (2005) 33-38
36. Kremers H.M., Reinalda M.S., Crowson C.S., Zinsmeister A.R., Hunder G.G., and Gabriel S.E. Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol 32 (2005) 65-73
37. Duhaut P., Berruyer M., Pinède L., Demolombe-Rague S., Loire R., Seydoux D., et al. Anticardiolipin antibodies and giant cell arteritis: a prospective, multicenter case-control study. Arthritis Rheum 41 (1998) 701-709
38. Liozon E., Roblot P., Paire D., Loustaud V., Liozon F., Vidal E., et al. Anticardiolipin antibody levels predicts flares and relapses in patients with giant-cell (temporal) arteritis. A longitudinal study of 58 biopsy-proven cases. Rheumatology 39 (2000) 1089-1094
39. Pego-Reigosa R., Garcia-Porrua C., Pineiro A., Dierssen T., Llorca J., and Gonzalez-Gay M.A. Predictors of cerebrovascular accidents in giant cell arteritis in a defined population. Clin Exp Rheumatol 22 (2004) S13-S17
40. Evans J.M., O'Fallon W.M., and Hunder G.G. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med 122 (1995) 502-507
41. Scully R.E., Mark E.J., McNeely W.F., and McNeely B.U. Case records of the Massachusetts General Hospital. N Engl J Med 329 (1993) 1028-1033
42. Nuenninghoff D.M., Hunder G.G., Christianson T.J., McClelland R.L., and Matteson E.L. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 48 (2003) 3522-3531
43. Nuenninghoff D.M., Hunder G.G., Christianson T.J., McClelland R.L., and Matteson E.L. Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 48 (2003) 3527-3532